In an open-label extension in 154 patients with birch pollen allergic rhinoconjunctivitis, two years of pre-seasonal subcutaneous EP-088_T502 was associated with 47.5% and 51.8% lower median symptom-medication scores than the earlier placebo group, and 36.5% in follow-up.
RCTn = 154
Mösges et al. Sustained Clinical Improvement in Birch Pollen Allergy After Two Pre-Seasonal Short Courses of Allergen-Specific Immunotherapy: A Long-Term Open-Label Extension Study